Panacea Index Logo

Command Palette

Search for a command to run...

Mind Your Heart-II: Protocol for a behavioral randomized controlled trial of mindfulness training to promote self-care in patients with comorbid heart failure and cognitive impairment.

Contemporary clinical trials
March 1, 2023
Natalie G Keirns et al. (11 authors)
Clinical Trial ProtocolJournal ArticleResearch Support, N.I.H., ExtramuralHuman StudyClinical
Study Details

Study Goal

The researchers aimed to investigate whether mindfulness training (MT) improves cognitive function, interoception, and vagal control, leading to enhanced heart failure (HF) self-care in patients with comorbid HF and mild cognitive impairment.

Results Summary

The study hypothesizes that MT will improve cognitive function, interoception, and vagal control, resulting in better HF self-care compared to control participants, but results are pending as the study is ongoing.

Population

English or Spanish-speaking patients with comorbid chronic HF and mild cognitive impairment (n=176).

Effective Dosage

8-week phone-delivered MT + Enhanced Usual Care (EUC).

Duration

8 weeks (with follow-up assessments at 3 and 9 months).

Interactions

None mentioned

Extracted Claims (8)
InterventionDirectionEndpointPopulationDosageImpactClaim #
Mindfulness training (MT)
increase
cognitive function
-
-
has been shown to improve
#1
Mindfulness training (MT)
increase
interoception
-
-
has been shown to improve
#2
Mindfulness training (MT)
increase
cognitive function
patients with comorbid HF and mild cognitive impairment
-
will improve
#3
Mindfulness training (MT)
increase
interoception
patients with comorbid HF and mild cognitive impairment
-
will improve
#4
Mindfulness training (MT)
increase
vagal control
patients with comorbid HF and mild cognitive impairment
-
will improve
#5
Mindfulness training (MT)
increase
HF self-care
patients with comorbid HF and mild cognitive impairment
-
resulting in enhanced
#6
phone-based MT
increase
HF self-care
HF patients with comorbid cognitive impairment
-
may be a key tool for improving
#7
phone-based MT
increase
clinical outcomes
HF patients with comorbid cognitive impairment
-
possibly improving
#8
Abstract

BACKGROUND: Heart failure (HF) self-care is a robust predictor of prognosis in HF patients. Cognitive impairment is a common comorbidity in HF patients and constitutes a major challenge to HF self-care. Mindfulness training (MT) has been shown to improve cognitive function and interoception, two components essential to promoting effective HF self-care. OBJECTIVES: The aims of the Mind Your Heart-II (MYH-II) study are to investigate the effects of MT on HF self-care via changes in cognitive function and interoception in patients with comorbid HF and cognitive impairment, and to study the process by which MT can improve cognitive function via vagal control. We hypothesize that MT will improve cognitive function, interoception, and vagal control, resulting in enhanced HF self-care, compared to control participants. METHODS: MYH-II is a mechanistic parallel phase II behavioral randomized controlled trial. We will enroll 176 English or Spanish-speaking patients with comorbid chronic HF and mild cognitive impairment. Participants will be randomized to either: (1) 8-week phone-delivered MT + Enhanced Usual Care (EUC), or (2) EUC alone. Participants will complete baseline, end-of-treatment (3 months), and follow-up (9 months) assessments. The primary outcome is cognitive function (NIH Toolbox Fluid Cognition Composite Score). Additional key outcomes include: interoception (heartbeat tracking task, Multidimensional Assessment of Interoceptive Awareness), HF self-care (Self-Care of Heart Failure Index v7.2), and vagal control (high-frequency heart rate variability). IMPLICATIONS: If study hypotheses are confirmed, phone-based MT may be a key tool for improving HF self-care, and possibly clinical outcomes, in HF patients with comorbid cognitive impairment.

Medical Subject Headings (MeSH)
HumansMindfulnessSelf CareTreatment OutcomeHeart FailureComorbidityCognitive DysfunctionRandomized Controlled Trials as TopicClinical Trials, Phase II as Topic
Study Links
Quality Scores
SafetyNot Assessed
Efficacy75/10
Quality85/10
Citation Metrics
Total Citations2
Citations/Year1.0
Relative Citation Ratio0.79
NIH Percentile41.6%
Research Impact Scores
APT Score0.50
Weight Score2.62
Normalized Score0.67
Related Supplements